Flag of the European Union EU Clinical Trials Register Help

Clinical trials for - Crohn’s Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,525 result(s) found for: - Crohn’s Disease. Displaying page 261 of 1,427.
    «« First « Previous 257  258  259  260  261  262  263  264  265  Next» Last»»
    EudraCT Number: 2013-003331-30 Sponsor Protocol Number: GO28915 Start Date*: 2014-03-03
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON−SMALL CELL LUNG CAN...
    Medical condition: NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) FI (Completed) IT (Completed) DE (Completed) PT (Completed) HU (Completed) NL (Completed) ES (Completed) PL (Completed) GR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005476-33 Sponsor Protocol Number: I4C-MC-JTBB Start Date*: 2013-08-27
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non–Small Cell Lung Cancer Patients with Activating EGFR Mutations ...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed) FR (Completed) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003859-11 Sponsor Protocol Number: MO41552 Start Date*: 2022-02-03
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WI...
    Medical condition: Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000259-99 Sponsor Protocol Number: RG_13-277 Start Date*: 2014-08-29
    Sponsor Name:University of Birmingham
    Full Title: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
    Medical condition: Recurrent and refractory Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015567 Ewing's tumor localized LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015763 Extra-osseous Ewing's sarcoma NOS LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015566 Ewing's tumor LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015762 Extra-osseous Ewing's sarcoma non-metastatic LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015761 Extra-osseous Ewing's sarcoma metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015569 Ewing's tumor recurrent LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015568 Ewing's tumor metastatic LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058252 Ewing's tumour recurrent LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058253 Ewing's tumour metastatic LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058254 Ewing's tumour localised LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015564 Ewing's sarcoma recurrent PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015759 Extra-osseous Ewing's sarcoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015764 Extra-osseous Ewing's sarcoma recurrent PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015570 Ewing's tumour LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015563 Ewing's sarcoma NOS LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) FI (Trial now transitioned) DK (Trial now transitioned) DE (Ongoing) HU (Completed) CZ (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) PL (Completed) IT (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001292-23 Sponsor Protocol Number: B-701-U22 Start Date*: 2017-10-25
    Sponsor Name:Rainier Therapeutics, Inc.
    Full Title: A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined with Pembrolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed F...
    Medical condition: Locally advanced or Metastatic Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Prematurely Ended) NL (Completed) PL (Completed) SE (Completed) ES (Prematurely Ended) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004886-29 Sponsor Protocol Number: MN39158 Start Date*: 2018-05-22
    Sponsor Name:Roche Farma SA (Soc unipersonal) que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd
    Full Title: A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSO...
    Medical condition: Multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) EE (Completed) IE (Completed) CZ (Completed) FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) FI (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) SI (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-017028-22 Sponsor Protocol Number: CSPP100A2365 Start Date*: 2010-06-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, 8 week study to evaluate the dose response, efficacy and safety of aliskiren in pediatric hypertensive patients 6-17 years of age.
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Ongoing) DE (Completed) SK (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000301-45 Sponsor Protocol Number: BAY94-8862/14563 Start Date*: 2011-05-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, multi-center study to assess safety and tolerability of different oral doses of BAY 94-8862 in subjects with stable chronic heart failure with left ventricular systolic...
    Medical condition: Stable chronic heart failure subjects with left ventricular systolic dysfunction and mild (Part A) or moderate (Part B) chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) DK (Completed) BE (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-017029-20 Sponsor Protocol Number: CSPP100A2365E1 Start Date*: 2010-11-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, double-blind, randomized, 52 week extension study to evaluate the long term safety, tolerability and efficacy of aliskiren compared to enalapril in pediatric hypertensive patients 6-...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) HU (Completed) BE (Completed) FR (Ongoing) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-003963-30 Sponsor Protocol Number: D2456C00002 Start Date*: 2007-02-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil 32 mg and Hydro...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9 10020772 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) SK (Completed) HU (Completed) BE (Completed) MT (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005718-19 Sponsor Protocol Number: D2456C00001 Start Date*: 2006-07-17
    Sponsor Name:AstraZeneca AB
    Full Title: A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothia...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) DE (Completed) SE (Completed) NL (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005811-16 Sponsor Protocol Number: OMB110913 Start Date*: 2008-12-22
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GR (Completed) IT (Completed) ES (Completed) GB (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-005068-13 Sponsor Protocol Number: I4T-MC-JVDE Start Date*: 2015-08-07
    Sponsor Name:Eli Lilly and Company
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma a...
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) CZ (Completed) PL (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001155-39 Sponsor Protocol Number: CO40778 Start Date*: 2019-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS WITH LOCALLY ADVANCED OR METASTATIC SOLID OR PRIMARY CNS TUMORS AND/OR WHO HAVE NO SATISFACTORY ...
    Medical condition: Solid tumors and primary central nervous system (CNS) tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003945-33 Sponsor Protocol Number: RV-MM-PI-280 Start Date*: 2009-01-16
    Sponsor Name:Gesellschaft für Medizinische Innovation –Hämatologie und Onkologie mbH (GMIHO)
    Full Title: A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma.
    Medical condition: Patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001490-40 Sponsor Protocol Number: 3005019 Start Date*: 2012-04-03
    Sponsor Name:ORION CORPORATION ORION PHARMA
    Full Title: Comparative evaluation of the effects of dexmedetomidine and propofol on patient/ventilator interaction in difficult-to-wean mechanically ventilated patients; a prospective, open, randomised, mul...
    Medical condition: Patients requiring mechanical ventilation and sedation in the ICU
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10039897 Sedation PT
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006304-13 Sponsor Protocol Number: ASCOMCOGI Start Date*: 2012-06-26
    Sponsor Name:AZIENDA OSPEDALIERA CARDARELLI
    Full Title: Effetto del precursore colinergico colina alfoscerato sui sintomi cognitivi e comportamentali in pazienti affetti da danno cognitivo lieve (mild cognitive impairment)
    Medical condition: mild cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005296-81 Sponsor Protocol Number: BMN-051-303 Start Date*: 2016-05-02
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A 24 week Randomized Double-Blind, Placebo-Controlled Study followed by 72 week open-label extension to assess the efficacy, safety and tolerability of drisapersen sodium in subjects with Duchenne ...
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001193-14 Sponsor Protocol Number: BAY85-3934/15141 Start Date*: 2013-12-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, placebo-controlled, double-blind, parallel group, multicenter study to investigate the efficacy and safety of 5 fixed doses of BAY 85- 3934 administered orally in the correction of an...
    Medical condition: Anaemia of Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004851 10058123 Renal anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) HU (Completed) BG (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000624-16 Sponsor Protocol Number: LOEWE_B4 Start Date*: 2011-11-28
    Sponsor Name:Justus Liebig Universität Gießen
    Full Title: Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome Male infertility with infection and inflammation -MIBIE-
    Medical condition: infertility and inflammatory urogenital diseases as a result of the metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10046694 Urogenital disorder PT
    14.0 10027433 - Metabolism and nutrition disorders 10052066 Metabolic syndrome PT
    14.0 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 257  258  259  260  261  262  263  264  265  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 06:28:42 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA